Therapeutic Peptide Modelling
Keywords: Cancer, QM/MM, NOESY, Gaussian 09, AMBER
Peptides present themselves as promising drug candidates, but the body’s natural proteolytic degradation pathways have hindered their application. Peptide design, however, can benefit significantly from the synthetic incorporation of non-standard amino acids such as β-amino acids, D-amino acids, and α,β-dehydroamino acids (ΔAAs), which are resistant to proteolysis. The literature is replete with a diversity of ‘designer residues’ used to fine-tune backbone conformations, side-chain functionality, and reactivity. One type of residue that merits further exploration is dehydroamino acids. Dehydroamino acid-containing peptides exhibit potent natural antibiotic, antifungal, antitumor, and phytotoxic bioactivity.
For example, Yaku’amide A is an extremely rare peptide isolated from the deep-sea sponge Ceratopsion sp. Identification and characterization of this peptide unveiled its curious structural profile and several dehydroamino acids. When tested against an array of 39 human cancer cell lines, YA exhibited cytotoxicity against P388 murine leukemia cells via a potentially novel mode of action. Unfortunately, many medically relevant peptides, such as Yaku’amide, often contain non-standard amino acids and require parameterization for computational studies. One approach to handling complex peptides lacking robust parameters is quantum mechanics (QM)/molecular mechanic (MM) hybrid simulations that rely on forcefields and ab initio calculations to balance the cost-accuracy tradeoff.
Related Publications: